Jiangsu Jiangshan Pharmaceutical Co Ltd, based in the county-level city of Jingjiang – administered by Taizhou, in East China's Jiangsu province – recently announced an equity restructuring, with former shareholder DSM-Firmenich transferring its 100 percent stake on March 11.
The gate for Jiangsu Jiangshan Pharmaceutical Co Ltd in Jingjiang city. [Photo/zhjjwx.jsjjw.cn]
Following the transfer, DSM-Jiangshan resumed its name change to Jiangsu Jiangshan Pharmaceutical Co Ltd. This marks the beginning of a new phase for this once leading company in China's vitamin C industry.
Established in 1990, Jiangsu Jiangshan Pharmaceutical Co Ltd was one of Jingjiang's earliest Sino-foreign joint ventures and was a pioneer in vitamin C API production in China.
Over 35 years, it became a global leader, contributing significantly to the city's economic and social development.
After several equity changes, the company has officially entered a restart phase, prompting optimism among its nearly 1,300 employees.
Company chairman, Chang Liang, emphasized that its focus was now on high-quality vitamin C products and the development of new, locally anchored synthetic biology initiatives.
Chang also highlighted plans for a new synthetic biology industrial park, aiming to accelerate research and development and solidify the city's position as a biomedicals industry hub.